Pfizer to acquire Wyeth

A MERG E R that will create one of the world''s largest biopharmaceutical companies is in the offing with $68- billion acquisition of Wyeth by Pfizer Inc. Geographically, the combination will enhance Pfizer and Wyeth''s compelling portfolios in important growth areas. Based on IMS data, the combined company will be number one in terms of biopharmaceutical revenues in the United States with an approximately 12% market share; in Europe with an approximately 10% share; in Asia (ex- Japan) with an approximately 7% share; in Japan with a 6% share; and in Latin America with a 6% share. Pfizer and Wyeth''s combined presence will be significant in highgrowth emerging markets, such as Latin America , the Middle East and China, where Wyeth has an impressive presence in infant nutritionals and Pfizer is a recognized leader in pharmaceuticals. With its broad and diversified global product portfolio and reduced dependence on small molecules, the new company will be positioned for improved, consistent, and stable top-line and EPS growth and sustainable shareholder value in the short and long term. It is expected that no drug will account for more than 10% of the combined company''s revenue in 2012.Air Jordan V 5 Shoes